Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Recruiting 2Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 5Observational 4

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Breast Neoplasms 2433Neoplasms 1842Carcinoma, Non-Small-Cell Lung 1609Prostatic Neoplasms 1312Colorectal Neoplasms 1144Lung Neoplasms 991Neoplasm Metastasis 835Multiple Myeloma 800Leukemia, Myeloid, Acute 778Ovarian Neoplasms 685Pancreatic Neoplasms 671Melanoma 667Squamous Cell Carcinoma of Head and Neck 592Carcinoma, Hepatocellular 570Recurrence 568Brain Neoplasms 528Glioblastoma 519Stomach Neoplasms 503Head and Neck Neoplasms 502Triple Negative Breast Neoplasms 473Lymphoma 461Uterine Cervical Neoplasms 457Carcinoma, Renal Cell 429Precursor Cell Lymphoblastic Leukemia-Lymphoma 421Lymphoma, Non-Hodgkin 390Endometrial Neoplasms 386Sarcoma 369Urinary Bladder Neoplasms 356Lymphoma, Large B-Cell, Diffuse 356Lymphoma, Follicular 356

Interventions

Sirolimus 2temsirolimus 1carbon-11 acetate 1Valproic Acid 1Immunoglobulin G 1Imatinib Mesylate 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Lymphangioleiomyomatosis × 1 year × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT01799538 2026-05-01

Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
100 enrolled

Lymphangioleiomyomatosis

NCT03304678 2026-02-18

Discovery of Sirolimus Sensitive Biomarkers in Blood

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
33 enrolled 6 charts

Lymphangioleiomyomatosis

NCT05467397 2026-01-21

Feasibility of [11C]Acetate-PET in LAM and TSC

Brigham and Women's Hospital

Phase 1/2 Active not recruiting
7 enrolled 6 charts

Tuberous Sclerosis, Lymphangioleiomyomatosis

NCT06889168 2026-01-21

LAMP-2

Columbia University

Phase 1 Recruiting
20 enrolled

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡